Expression of HIV gp120 protein increases sensitivity to the rewarding properties of methamphetamine in mice

Addiction Biology

Volumn 19, Issue 4, 2014, Pages 593-605

  Kesby, James P ^a   Hubbard, David T ^a   Markou, Athina ^a   Semenova, Svetlana ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Conditioned place preference; food maintained responding; oral self administration; pharmacokinetics; quinine; saccharin

Indexed keywords

AMPHETAMINE; GLYCOPROTEIN GP 120; METHAMPHETAMINE; QUININE; CENTRAL STIMULANT AGENT; SACCHARIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITION; CONTROLLED STUDY; DRINKING; DRUG SENSITIVITY; FEMALE; FOOD; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MOTIVATION; MOUSE; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REINFORCEMENT; REWARD; STATE DEPENDENT LEARNING; TASTE PREFERENCE; ANALYSIS OF VARIANCE; ANIMAL; ANIMAL BEHAVIOR; BIOSYNTHESIS; C57BL MOUSE; CONDITIONED REFLEX; DECISION MAKING; DISEASE MODEL; DOSE RESPONSE; DRUG ABUSE; DRUG EFFECTS; GENE EXPRESSION; GENETICS; LEARNING; PHYSIOLOGY; SEX RATIO;

AMPHETAMINE-RELATED DISORDERS; ANALYSIS OF VARIANCE; ANIMALS; ASSOCIATION LEARNING; BEHAVIOR, ANIMAL; CENTRAL NERVOUS SYSTEM STIMULANTS; CHOICE BEHAVIOR; CONDITIONING, CLASSICAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION; HIV ENVELOPE PROTEIN GP120; MALE; METHAMPHETAMINE; MICE; MICE, INBRED C57BL; MOTIVATION; QUININE; REWARD; SACCHARIN; SEX DISTRIBUTION;

EID: 84904250657     PISSN: 13556215     EISSN: 13691600     Source Type: Journal    
DOI: 10.1111/adb.12023     Document Type: Article

References (68)

1. Achat-Mendes C, Ali SF, Itzhak Y, (2005) Differential effects of amphetamines-induced neurotoxicity on appetitive and aversive Pavlovian conditioning in mice. Neuropsychopharmacology 30: 1128-1137. (Pubitemid 40720971)
2. Achim CL, Adame A, Dumaop W, Everall IP, Masliah E, (2009) Increased accumulation of intraneuronal amyloid β in HIV-infected patients. J Neuroimmune Pharmacol 4: 190-199.
3. Agrawal L, Louboutin JP, Marusich E, Reyes BAS, Van Bockstaele EJ, Strayer DS, (2010) Dopaminergic neurotoxicity of HIV-1 gp120: reactive oxygen species as signaling intermediates. Brain Res 1306: 116-130.
4. Aylward EH, Henderer JD, McArthur JC, Brettschneider PD, Harris GJ, Barta PE, Pearlson GD, (1993) Reduced basal ganglia volume in HIV-1-associated dementia: results from quantitative neuroimaging. Neurology 43: 2099-2104. (Pubitemid 23318887)
5. Bamford NS, Zhang H, Joyce JA, Scarlis CA, Hanan W, Wu NP, Andre VM, Cohen R, Cepeda C, Levine MS, Harleton E, Sulzer D, (2008) Repeated exposure to methamphetamine causes long-lasting presynaptic corticostriatal depression that is renormalized with drug readministration. Neuron 58: 89-103. (Pubitemid 351467027)
6. Belzung C, Barreau S, (2000) Differences in drug-induced place conditioning between BALB/c and C57Bl/6 mice. Pharmacol Biochem Behav 65: 419-423. (Pubitemid 30100672)
7. Berger JR, Nath A, (1997) HIV dementia and the basal ganglia. Intervirology 40: 122-131. (Pubitemid 28021606)
8. Berridge KC, (2007) The debate over dopamine's role in reward: the case for incentive salience. Psychopharmacology 191: 391-431. (Pubitemid 46355895)
9. Carey CL, Woods SP, Rippeth JD, Gonzalez R, Heaton RK, Grant I, (2006) Additive deleterious effects of methamphetamine dependence and immunosuppression on neuropsychological functioning in HIV infection. AIDS Behav 10: 185-190.
10. Carr GD, White NM, (1986) Anatomical disassociation of amphetamine's rewarding and aversive effects: an intracranial microinjection study. Psychopharmacology 89: 340-346. (Pubitemid 16036191)
11. Carrico AW, (2011) Substance use and HIV disease progression in the HAART era: implications for the primary prevention of HIV. Life Sci 88: 940-947.
12. Chana G, Everall IP, Crews L, Langford D, Adame A, Grant I, Cherner M, Lazzaretto D, Heaton R, Ellis R, Masliah E, (2006) Cognitive deficits and degeneration of interneurons in HIV+ methamphetamine users. Neurology 67: 1486-1489. (Pubitemid 44632083)
13. Childs E, de Wit H, (2009) Amphetamine-induced place preference in humans. Biol Psychiatry 65: 900-904.
14. D'Hooge R, Franck F, Mucke L, De Deyn PP, (1999) Age-related behavioural deficits in transgenic mice expressing the HIV-1 coat protein gp120. Eur J Neurosci 11: 4398-4402. (Pubitemid 30009272)
15. Delgado MR, Nystrom LE, Fissell C, Noll DC, Fiez JA, (2000) Tracking the hemodynamic responses to reward and punishment in the striatum. J Neurophysiol 84: 3072-3077.
16. Di Chiara G, (2002) From rats to humans and return: testing addiction hypotheses by combined PET imaging and self-reported measures of psychostimulant effects. Commentary on Volkow et al. 'Role of dopamine in drug reinforcement and addiction in humans: results from imaging studies.' Behav Pharmacol 13: 371-377. (Pubitemid 35178834)
17. Di Chiara G, Imperato A, (1988) Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A 85: 5274-5278.
18. Eddleston M, Mucke L, (1993) Molecular profile of reactive astrocytes: implications for their role in neurological disease. Neuroscience 54: 15-36. (Pubitemid 23147085)
19. Elliott R, Newman JL, Longe OA, Deakin JFW, (2003) Differential response patterns in the striatum and orbitofrontal cortex to financial reward in humans: a parametric functional magnetic resonance imaging study. J Neurosci 23: 303-307. (Pubitemid 36050431)
20. Ellis RJ, Childers ME, Cherner M, Lazzaretto D, Letendre S, Grant I, (2003) Increased human immunodeficiency virus loads in active methamphetamine users are explained by reduced effectiveness of antiretroviral therapy. J Infect Dis 188: 1820-1826. (Pubitemid 38064866)
21. Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, Hanson GR, (2007) New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol 47: 681-698.
22. Gardner EL, (2005) Endocannabinoid signaling system and brain reward: emphasis on dopamine. Pharmacol Biochem Behav 81: 263-284. (Pubitemid 40807127)
23. Gosnell BA, Krahn DD, Yracheta JM, Harasha BJ, (1998) The relationship between intravenous cocaine self-administration and avidity for saccharin. Pharmacol Biochem Behav 60: 229-236. (Pubitemid 28236635)
24. Hestad K, McArthur JH, Dal Pan GJ, Selnes OA, Nance-Sproson TE, Aylward E, Mathews VP, McArthur JC, (1993) Regional brain atrophy in HIV-1 infection: association with specific neuropsychological test performance. Acta Neurol Scand 88: 112-118. (Pubitemid 23247973)
25. Hinkin CH, Hardy DJ, Mason KI, Catellon SA, Lam MN, Stefaniak M, Zolnikov B, (2002) Verbal and spatial working memory performance among HIV-infected adults. J Int Neuropsychol Soc 8: 532-538. (Pubitemid 34578318)
26. Hiroi N, White NM, (1991) The amphetamine conditioned place preference: differential involvement of dopamine receptor subtypes and 2 dopaminergic terminal areas. Brain Res 552: 141-152.
27. Hu S, Sheng WS, Lokensgard JR, Peterson PK, Rock RB, (2009) Preferential sensitivity of human dopaminergic neurons to gp120-induced oxidative damage. J Neurovirol 15: 401-410.
28. Ikemoto S, (2007) Dopamine reward circuitry: two projection systems from the ventral midbrain to the nucleus accumbens-olfactory tubercle complex. Brain Res Rev 56: 27-78. (Pubitemid 350110353)
29. Kamens HM, Burkhart-Kasch S, McKinnon CS, Li N, Reed C, Phillips TJ, (2005) Sensitivity to psychostimulants in mice bred for high and low stimulation to methamphetamine. Genes Brain Behav 4: 110-125. (Pubitemid 40333315)
30. Kass MD, Liu X, Vigorito M, Chang L, Chang SL, (2010) Methamphetamine-induced behavioral and physiological effects in adolescent and adult HIV-1 transgenic rats. J Neuroimmune Pharmacol 5: 566-573.
31. Kieburtz K, Ketonen L, Cox C, Grossman H, Holloway R, Booth H, Hickey C, Feigin A, Caine ED, (1996) Cognitive performance and regional brain volume in human immunodeficiency virus type 1 infection. Arch Neurol 53: 155-158. (Pubitemid 26055262)
32. Krucker T, Toggas SM, Mucke L, Siggins GR, (1998) Transgenic mice with cerebral expression of human immunodeficiency virus type-1 coat protein gp120 show divergent changes in short- and long-term potentiation in CA1 hippocampus. Neuroscience 83: 691-700. (Pubitemid 28068890)
33. Kumar AM, Fernandez JB, Singer EJ, Commins D, Waldrop-Valverde D, Ownby RL, Kumar M, (2009) Human immunodeficiency virus type 1 in the central nervous system leads to decreased dopamine in different regions of postmortem human brains. J Neurovirol 15: 257-274.
34. Liu X, Chang L, Vigorito M, Kass M, Li H, Chang SL, (2009) Methamphetamine-induced behavioral sensitization is enhanced in the HIV-1 transgenic rat. J Neuroimmune Pharmacol 4: 309-316.
35. Marquez C, Mitchell SJ, Hare CB, John M, Klausner JD, (2009) Methamphetamine use, sexual activity, patient-provider communication, and medication adherence among HIV-infected patients in care, San Francisco 2004-2006. AIDS Care 21: 575-582.
36. Masliah E, Ge N, Achim CL, Hansen LA, Wiley CA, (1992) Selective neuronal vulnerability in HIV encephalitis. J Neuropathol Exp Neurol 51: 585-593.
37. Masliah E, Heaton RK, Marcotte TD, Ellis RJ, Wiley CA, Mallory M, Achim CL, McCutchan JA, Nelson JA, Atkinson JH, Grant I, (1997) Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders. Ann Neurol 42: 963-972. (Pubitemid 28008427)
38. Meisch RA, (2001) Oral drug self-administration: an overview of laboratory animal studies. Alcohol 24: 117-128. (Pubitemid 32755917)
39. 1 subunit. Eur J Neurosci 19: 151-158. (Pubitemid 38122081)
40. Miyazaki I, Asanuma M, Diaz-Corrales FJ, Fukuda M, Kitaichi K, Miyoshi K, Ogawa N, (2006) Methamphetamine-induced dopaminergic neurotoxicity is regulated by quinone-formation-related molecules. FASEB J 20: 571-573. (Pubitemid 46671253)
41. Moore DJ, Letendre SL, Morris S, Umlauf A, Deutsch R, Smith DM, Little S, Rooney A, Franklin DR, Gouaux B, LeBlanc S, Rosario D, Fennema-Notestine C, Heaton RK, Ellis RJ, Atkinson JH, Grant I, (2011) Neurocognitive functioning in acute or early HIV infection. J Neurovirol 17: 50-57.
42. Nagai T, Noda Y, Ishikawa K, Miyamoto Y, Yoshimura M, Ito M, Takayanagi M, Takuma K, Yamada K, Nabeshima T, (2005) The role of tissue plasminogen activator in methamphetamine-related reward and sensitization. J Neurochem 92: 660-667. (Pubitemid 40189468)
43. Narita M, Miyatake M, Narita M, Shibasaki M, Shindo K, Nakamura A, Kuzumaki N, Nagumo Y, Suzuki T, (2006) Direct evidence of astrocytic modulation in the development of rewarding effects induced by drugs of abuse. Neuropsychopharmacology 31: 2476-2488. (Pubitemid 44607065)
44. Nath A, (2010) Human immunodeficiency virus-associated neurocognitive disorder Pathophysiology in relation to drug addiction. In:, Uhl GR, ed. Addiction Reviews 2, pp. 122-128. Hoboken, NJ: Wiley.
45. Navia BA, Cho ES, Petito CK, Price RW, (1986) The AIDS dementia complex: II. Neuropathology. Ann Neurol 19: 525-535. (Pubitemid 16085186)
46. Nestler EJ, (2005) Is there a common molecular pathway for addiction? Nat Neurosci 8: 1445-1449. (Pubitemid 41573654)
47. Neuen-Jacob E, Arendt G, Wendtland B, Jacob B, Schneeweis M, Wechsler W, (1993) Frequency and topographical distribution of CD68-positive macrophages and HIV-1 core proteins in HIV-associated brain lesions. Clin Neuropathol 12: 315-324. (Pubitemid 23361930)
48. O'Brien CP, Gardner EL, (2005) Critical assessment of how to study addiction and its treatment: human and non-human animal models. Pharmacol Ther 108: 18-58. (Pubitemid 41377117)
49. Perry JL, Anderson MM, Nelson SE, Carroll ME, (2007) Acquisition of i.v. cocaine self-administration in adolescent and adult male rats selectively bred for high and low saccharin intake. Physiol Behav 91: 126-133. (Pubitemid 46616884)
50. Purohit V, Rapaka R, Shurtleff D, (2011) Drugs of abuse, dopamine, and HIV-associated neurocognitive disorders/HIV-associated dementia. Mol Neurobiol 44: 102-110.
51. Rippeth JD, Heaton RK, Carey CL, Marcotte TD, Moore DJ, Gonzalez R, Wolfson T, Grant I, (2004) Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons. J Int Neuropsychol Soc 10: 1-14. (Pubitemid 38128457)
52. Roberts AJ, Maung R, Sejbuk NE, Ake C, Kaul M, (2010) Alteration of methamphetamine-induced stereotypic behaviour in transgenic mice expressing HIV-1 envelope protein gp120. J Neurosci Methods 186: 222-225.
53. Roberts DCS, Bennett SAL, (1993) Heroin self-administration in rats under a progressive ratio schedule of reinforcement. Psychopharmacology 111: 215-218. (Pubitemid 23135082)
54. Robinson L, Rempel H, (2006) Methamphetamine use and HIV symptom self-management. J Assoc Nurses AIDS Care 17: 7-14. (Pubitemid 44345246)
55. Scibelli AC, McKinnon CS, Reed C, Burkhart-Kasch S, Li N, Baba H, Wheeler JM, Phillips TJ, (2011) Selective breeding for magnitude of methamphetamine-induced sensitization alters methamphetamine consumption. Psychopharmacology 214: 791-804.
56. Semple SJ, Patterson TL, Grant I, (2002) Motivations associated with methamphetamine use among HIV+ men who have sex with men. J Subst Abuse Treat 22: 149-156. (Pubitemid 34597219)
57. Shoptaw S, Reback CJ, (2006) Associations between methamphetamine use and HIV among men who have sex with men: a model for guiding public policy. J Urban Health 83: 1151-1157. (Pubitemid 46024892)
58. Silverstein PS, Shah A, Gupte R, Liu X, Piepho RW, Kumar S, Kumar A, (2011) Methamphetamine toxicity and its implications during HIV-1 infection. J Neurovirol 17: 401-415.
59. Stefurak TL, van der Kooy D, (1992) Saccharin rewarding, conditioned reinforcing, and memory-improving properties: mediation by isomorphic or independent processes. Behav Neurosci 106: 125-139.
60. Sulzer D, Sonders MS, Poulsen NW, Galli A, (2005) Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol 75: 406-433. (Pubitemid 40834286)
61. Theodore S, Cass WA, Nath A, Maragos WF, (2007) Progress in understanding basal ganglia, dysfunction as a common target for methamphetamine abuse and HIV-1 neurodegeneration. Curr HIV Res 5: 301-313. (Pubitemid 46785066)
62. Toggas SM, Masliah E, Rockenstein EM, Rall GF, Abraham CR, Mucke L, (1994) Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice. Nature 367: 188-193. (Pubitemid 24031702)
63. Toneatto S, Finco O, van der, Putten H, Abrignani S, Annunziata P, (1999) Evidence of blood-brain barrier alteration and activation in HIV-1 gp120 transgenic mice. AIDS 13: 2343-2348.
64. Turchan J, Anderson C, Hauser KF, Sun QM, Zhang JY, Liu Y, Wise PM, Kruman I, Maragos W, Mattson MP, Booze R, Nath A, (2001) Estrogen protects against the synergistic toxicity by HIV proteins, methamphetamine and cocaine. BMC Neurosci 2: Article number 3.
65. Tzschentke TM, (2007) Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade. Addict Biol 12: 227-462. (Pubitemid 47196347)
66. Weis S, Haug H, Budka H, (1993) Astroglial changes in the cerebral-cortex of AIDS brains: a morphometric and immunohistochemical investigation. Neuropathol Appl Neurobiol 19: 329-335. (Pubitemid 23237484)
67. Wise RA, (2004) Dopamine, learning and motivation. Nat Rev Neurosci 5: 483-494. (Pubitemid 38715515)
68. Zombeck JA, Gupta T, Rhodes JS, (2009) Evaluation of a pharmacokinetic hypothesis for reduced locomotor stimulation from methamphetamine and cocaine in adolescent versus adult male C57BL/6J mice. Psychopharmacology 201: 589-599.